Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Other financing activities (2020 - 2023)

Xeris Biopharma Holdings' Other financing activities history spans 4 years, with the latest figure at $1.2 million for Q4 2023.

  • For the quarter ending Q4 2023, Other financing activities rose 1875.0% year-over-year to $1.2 million, compared with a TTM value of $1.2 million through Dec 2023, down 75.7%, and an annual FY2023 reading of $1.2 million, down 75.7% over the prior year.
  • Other financing activities for Q4 2023 was $1.2 million at Xeris Biopharma Holdings, up from $60000.0 in the prior quarter.
  • The five-year high for Other financing activities was $3.6 million in Q1 2022, with the low at -$54000.0 in Q4 2021.
  • Average Other financing activities over 4 years is $760500.0, with a median of $109500.0 recorded in 2022.
  • Year-over-year, Other financing activities plummeted 334.78% in 2021 and then skyrocketed 1875.0% in 2023.
  • Tracing XERS's Other financing activities over 4 years: stood at $23000.0 in 2020, then tumbled by 334.78% to -$54000.0 in 2021, then surged by 211.11% to $60000.0 in 2022, then skyrocketed by 1875.0% to $1.2 million in 2023.
  • Per Business Quant, the three most recent readings for XERS's Other financing activities are $1.2 million (Q4 2023), $60000.0 (Q4 2022), and $159000.0 (Q3 2022).